Abstract
Background: CSA ± Cheyne–Stokes Respiration (CSR) is common in CHF pts and is associated with a bad prognosis.
Purpose: The FACE study is investigating ASV use over 2 years' follow-up (FU) in CHF pts eligible for this treatment. Baseline characteristics and interim 3-month FU data are presented.
Methods: Baseline cardiac function, respiratory/sleep data, Epworth Sleepiness Scale (ESS) score and QoL (Minnesota Living with HF questionnaire) were assessed. Primary endpoints are all-cause or cardiovascular-related death, and all-cause unplanned hospitalisation or hospitalisation for worsening HF.
Results: 311 CHF pts with CSA-CSR have been enrolled. Baseline characteristics were: age 70.1±11.4 y, 87% male, body mass index 28.0±5.2 kg/m2, ischaemic aetiology 53%. Left ventricular ejection fraction was moderately or severely reduced in 52% and 17% of pts, respectively. Mean apnoea-hypopnoea index (AHI) was 42.7±17.4/h and 69% had predominantly CSA. ESS score was 7.5±5.0. Major comorbidities were hypertension (73%), dyslipidaemia (59%), atrial fibrillation (43%), diabetes (37%) or cerebrovascular event (29%). 29% of pts declined ASV treatment (controls). At 3-month FU, AHI was 6±7/h in the ASV group vs 27±16/h in controls (p<0.001). Mean ASV use was 5.5 h/night. Three-month event rates for all primary endpoints were similar in both groups but all-cause unplanned hospitalisation rate was lower in the ASV group vs. controls (15% vs 32%, p=0.014).
Conclusion: Although CHF patients with CSA have severe multiple cardio-metabolic comorbidities, ASV treatment appears to improve health status at 3 months.
- Copyright ©ERS 2015